Gepotidacin

The FDA has approved gepotidacin (Blujepa), the first new class of oral antibiotics for urinary tract infections in nearly 30 years, addressing growing concerns about antimicrobial resistance.

GSK's Blujepa (gepotidacin) has received FDA approval for treating uncomplicated urinary tract infections, marking the first new class of oral antibiotics for UTIs in nearly three decades.

Gepotidacin represents the first potential new oral antibiotic for urinary tract infections in over 20 years, offering a novel mechanism that overcomes fluoroquinolone resistance.

The FDA is set to decide on Bavarian Nordic's CHIKV VLP vaccine for chikungunya, potentially the first VLP-based option in the U.S.

Phase 3 trials indicate zoliflodacin and gepotidacin as potential oral treatments for gonorrhea, including drug-resistant strains, addressing the urgent need for new antimicrobials.